Eisai Pledges $200M to Oncology Start-up H3
By BioWorld Today Staff Reports
Monday, January 31, 2011
Eisai Inc., of Woodcliff Lake, N.J., the U.S. pharmaceutical operation of Tokyo-based Eisai Co. Ltd., has pledged as much as $200 million in research funding to start-up H3 Biomedicine, of Cambridge, Mass., which hopes to develop oncology treatments genetically tailored to patients' cancers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.